DK2136801T3 - Kappa-opiat-agonister til behandling af diarré-dominerende og afvekslende irritabel tarmsyndrom - Google Patents

Kappa-opiat-agonister til behandling af diarré-dominerende og afvekslende irritabel tarmsyndrom

Info

Publication number
DK2136801T3
DK2136801T3 DK08731748.3T DK08731748T DK2136801T3 DK 2136801 T3 DK2136801 T3 DK 2136801T3 DK 08731748 T DK08731748 T DK 08731748T DK 2136801 T3 DK2136801 T3 DK 2136801T3
Authority
DK
Denmark
Prior art keywords
opiat
diary
irritable
kappa
agonists
Prior art date
Application number
DK08731748.3T
Other languages
Danish (da)
English (en)
Inventor
Allen Mangel
Original Assignee
Tioga Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceuticals Inc filed Critical Tioga Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2136801T3 publication Critical patent/DK2136801T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
DK08731748.3T 2007-03-30 2008-03-07 Kappa-opiat-agonister til behandling af diarré-dominerende og afvekslende irritabel tarmsyndrom DK2136801T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92084107P 2007-03-30 2007-03-30
PCT/US2008/056317 WO2008121496A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Publications (1)

Publication Number Publication Date
DK2136801T3 true DK2136801T3 (da) 2012-12-17

Family

ID=39795494

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08731748.3T DK2136801T3 (da) 2007-03-30 2008-03-07 Kappa-opiat-agonister til behandling af diarré-dominerende og afvekslende irritabel tarmsyndrom

Country Status (19)

Country Link
US (2) US7960429B2 (cg-RX-API-DMAC10.html)
EP (3) EP2136801B1 (cg-RX-API-DMAC10.html)
JP (2) JP5416085B2 (cg-RX-API-DMAC10.html)
KR (2) KR101208326B1 (cg-RX-API-DMAC10.html)
CN (2) CN101677997B (cg-RX-API-DMAC10.html)
AU (1) AU2008232954A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0809651A2 (cg-RX-API-DMAC10.html)
CA (1) CA2682608A1 (cg-RX-API-DMAC10.html)
CY (1) CY1113317T1 (cg-RX-API-DMAC10.html)
DK (1) DK2136801T3 (cg-RX-API-DMAC10.html)
ES (1) ES2393815T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20120798T1 (cg-RX-API-DMAC10.html)
IL (1) IL201226A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009010409A (cg-RX-API-DMAC10.html)
PL (1) PL2136801T3 (cg-RX-API-DMAC10.html)
PT (1) PT2136801E (cg-RX-API-DMAC10.html)
RU (1) RU2441655C2 (cg-RX-API-DMAC10.html)
SI (1) SI2136801T1 (cg-RX-API-DMAC10.html)
WO (1) WO2008121496A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101677997B (zh) * 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
BR112015015258A2 (pt) 2012-12-24 2017-09-26 Neurogastrx Inc métodos para tratar distúrbios do trato gastrintestinal
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
JP6410641B2 (ja) 2015-03-04 2018-10-24 ローム株式会社 ワイヤレス送電装置、異物検出方法、充電器
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
EP3558300B1 (en) 2016-12-21 2021-11-24 Tioga Pharmaceuticals, Inc. Solid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
CN118512451A (zh) 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
EP4121083A4 (en) * 2020-03-18 2023-11-29 Cara Therapeutics, Inc. OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline
JP7464744B2 (ja) * 2020-10-20 2024-04-09 セトラスホールディングス株式会社 診療支援装置、診療支援方法、診療支援プログラム及び診療支援システム
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) * 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
GB8601796D0 (en) * 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
EP0330467A1 (en) 1988-02-23 1989-08-30 Glaxo Group Limited Heterocyclic compounds
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE3916663A1 (de) * 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
CA2021817C (en) * 1989-07-24 2000-09-26 William J. Mork Upholstered article of furniture with interchangeable seating module
EP0501997B1 (en) 1989-11-24 1997-01-29 Smithkline Beecham S.p.A. N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
DE69833000T2 (de) * 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
EP1093370B1 (en) * 1998-06-30 2006-02-22 Takeda Pharmaceutical Company Limited Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DE19849650A1 (de) * 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
DE60018225T2 (de) * 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) * 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
US20050176746A1 (en) * 2002-05-17 2005-08-11 Frank Weber Use of compounds that are effective as selective opiate receptor modulators
MXPA05002983A (es) * 2002-09-18 2005-06-22 Univ Missouri Analogos de opiato selectivos del receptor opioide d.
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
PL1644021T3 (pl) * 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ，インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂

Also Published As

Publication number Publication date
KR20120058614A (ko) 2012-06-07
EP2561870A1 (en) 2013-02-27
RU2441655C2 (ru) 2012-02-10
HK1139860A1 (en) 2010-09-30
SI2136801T1 (sl) 2013-01-31
AU2008232954A1 (en) 2008-10-09
RU2009140042A (ru) 2011-05-10
EP2136801A4 (en) 2010-05-26
EP2136801B1 (en) 2012-08-29
CN102641265A (zh) 2012-08-22
EP2136801A1 (en) 2009-12-30
CA2682608A1 (en) 2008-10-09
IL201226A0 (en) 2010-05-31
BRPI0809651A2 (pt) 2014-10-07
US20080242720A1 (en) 2008-10-02
JP2013173790A (ja) 2013-09-05
CY1113317T1 (el) 2016-04-13
US8877800B2 (en) 2014-11-04
PL2136801T3 (pl) 2013-01-31
KR101263225B1 (ko) 2013-05-13
AU2008232954A2 (en) 2011-12-01
JP5416085B2 (ja) 2014-02-12
KR101208326B1 (ko) 2012-12-05
EP2636407A2 (en) 2013-09-11
US20110046174A1 (en) 2011-02-24
CN101677997A (zh) 2010-03-24
EP2636407A3 (en) 2013-11-06
ES2393815T3 (es) 2012-12-28
MX2009010409A (es) 2010-03-29
KR20100016004A (ko) 2010-02-12
CN101677997B (zh) 2012-05-09
PT2136801E (pt) 2012-12-06
US7960429B2 (en) 2011-06-14
JP2010523492A (ja) 2010-07-15
WO2008121496A1 (en) 2008-10-09
HRP20120798T1 (hr) 2012-11-30

Similar Documents

Publication Publication Date Title
DK2252148T3 (da) Fremgangsmåder til behandling af irritabel tarmsyndrom
DK2297312T3 (da) Alpha-amylasevarianter af Bacillus subtilis og fremgangsmåder til anvendelse heraf
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK2133134T3 (da) Anordning og fremgangsmåde til behandling af udstødningsgas
DK3156069T3 (da) Sammensætninger, fremgangsmåder, og kits til fremkaldelse af et immunrespons
DK2454008T3 (da) Fremgangsmåde og indretning til de-noxing af røggasser
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2032156T3 (da) Sammensætninger og fremgangsmåder til levering af oxygen
DK2676967T3 (da) Fremgangsmåder til behandling af inflammatoriske og autoimmune sygdomme med natalizumab
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK2518655T3 (da) Anordning og fremgangsmåde til forebyggelse af hypoglykæmi
DK2102398T3 (da) Fremgangsmåde til fremstilling af en ankelsok og ankelsok opnået derved
DK2414507T3 (da) Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder
DK2131856T3 (da) Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
DK2467173T3 (da) Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
DK2247582T3 (da) Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf
DK3128014T3 (da) Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger
DK2144555T3 (da) Indretning og fremgangsmåde til transkutan bestemmelse af blodgasser
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK2227234T3 (da) Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf
DK2222314T3 (da) Anvendelser og midler til opnåelse af bronchorelaxation
DK2176603T3 (da) En indretning og en fremgangsmåde til fremstilling af isterninger